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Abstract In this study, using the microsphere method,
the hemodynamic response to endothelin-1 (ET-1) in
healthy and streptozotocin (STZ)-diabetic rats was evalu-
ated as well as the inﬂuences of inhibition of nitric oxide
(NO)-synthase using L-NAME (Nx-nitro-L-arginine
methyl ester) and the cyclooxygenase inhibitor indometh-
acin. Blood ﬂow (Q) was measured in tissues of interest for
vascular complications in diabetes such as kidney, eye,
brain, heart and skeletal muscle with the main focus on
ophthalmic circulation. Under resting conditions, evidence
for renal vasoconstriction was found in diabetic animals. In
both groups, administration of L-NAME reduced Q in all
investigated tissues indicating a basal NO inﬂuence. In the
normal rats, ET-1 induced a signiﬁcant increase in blood
pressure and intense vasoconstriction in all tissues except
in the choroid of the eye and in the brain, where it induced
an increased Q. In the STZ-diabetic rats, effects of ET-1
were less pronounced. Pretreatment with L-NAME, but not
the cyclooxygenase inhibitor, abolished the ET-1-induced
vasodilation in the choroid of both groups. Administration
of ET A receptor antagonist BQ-123 reduced the ET-1-
induced vasodilation in the choroid only in diabetic ani-
mals. In conclusion, evidence for altered vascular
endothelial response to ET-1 in STZ-diabetic animals was
found particularly in the ophthalmic circulation. The ﬁnd-
ings suggest differential involvement of receptors in the
response to ET-1 in normal and STZ-diabetic animals.
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Introduction
Impairment of endothelial cell function has been impli-
cated in the development of vascular complications to
diabetes mellitus such as renal failure and diabetic reti-
nopathy [1]. The peptide hormone endothelin-1 (ET-1),
produced by the vascular endothelial cells, is a potent
vasoconstrictor [2]. In addition, ET-1 has been shown to
interact with vasodilating nitric oxide (NO) [1, 3]. ET-1 has
also been found to have pro-inﬂammatory properties and to
promote vascular smooth muscle cell proliferation [4].
Furthermore, ET-1 has been shown to increase endothelial
cell permeability and extracellular matrix protein expres-
sion [5], and can contribute to remodeling of resistance
arteries [6] with changes in the microvasculature.
Increased expression of ET-1 has been demonstrated in
diabetes [5], and circulating levels of ET-1 have been
reported to be elevated in patients with type 2 diabetes [7].
In patients with proliferative diabetic retinopathy,
increased levels of ET-1 have been found in both plasma
and vitreous humor [8], suggesting involvement of ET-1 in
the development of proliferative diabetic retinopathy. In
the kidney, ET-1 is secreted by glomerular endothelial
cells, mesangial cells and epithelial cells. In humans, a
correlation between plasma or urinary levels of ET-1 and
signs of diabetic nephropathy such as increased glomerular
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albuminuria and uremia have been found [7, 9, 10].
ET-1 exerts its effects through activation of ET A and
B-receptors [11]. In the vasculature, the ET A-receptor is
mainly located on vascular smooth muscle cells and
mediates vasoconstriction. The ET B-receptor is primarily
located on endothelial cells, but may also be present on
vascular smooth muscle cells. Stimulation of the endothe-
lial ET B-receptor induces vasodilation through release of
NO and prostacyclin whereas stimulation of the vascular
smooth muscle cell ET B-receptors results in vasocon-
striction [12].
In the rat model of streptozotocin (STZ)-induced dia-
betes, changes in ET-1 production and function in line with
ﬁndings in humans have been found, such as elevated
plasma ET-1 levels [13], increase in immunoﬂuorescence
to anti-ET-1 in retinal capillaries [14] and reduced pro-
gression of diabetic nephropathy by ET A-receptor inhi-
bition [15]. In the present study, the microsphere method
was applied to investigate the hemodynamic response to
ET-1 before and after administration of ET A-receptor
antagonist BQ-123 in normal rats, and in rats with STZ-
induced diabetes, particularly in tissues of interest for the
development of diabetic microvascular complications such
as the kidney, eye, brain, heart and skeletal muscle. The
possible involvement of NO and prostacyclin pathways
was examined.
Materials and methods
Experiments were performed in accordance with the Dec-
laration of Helsinki and the guide for the care and use of
laboratory animals (DHEW publication, NIH 80-23) and
approved by the Animals Ethic Committee of the Univer-
sity of Uppsala. The animals were housed at the Hospital
Research Center with free access to water and food. A total
of 36 Sprague-Dawley (SpD) rats, obtained from Mo ¨lleg-
aard (Denmark), were included in the study. 16 animals
were made diabetic with an intravenous injection of
streptozotocin (Zanosar
; Pharmacia Upjohn, USA)
40 mg/kg. Animals were fasted overnight before STZ
administration and buprenorphin (Temgesic
; Meda,
Sweden) was used as analgesia. One week after the STZ-
injection, blood glucose levels were determined by tail vein
samples (Hemocue, Sweden) and all rats with blood glu-
cose levels greater than 20 mmol/l were considered dia-
betic and were included in the study. Blood ﬂow
(Q) determinations were performed 31 ± 2 days after STZ
administration, i.e. after 3 weeks of established hypergly-
cemia. The age was between 13 and 17 weeks and the
weight between 0.43 ± 0.01 kg for normal and
0.29 ± 0.02 kg for the diabetic rats (P\0.05). Blood
glucose measured immediately before the microsphere
procedure was 35.2 ± 1.3 mmol/l.
On the day of Q determination, animals were anaes-
thetized with thiobutabarbital 120 mg/kg (Inactin
; RBI,
USA). Body temperature was kept constant by a skin
thermistor and heating pad (Atew, Sweden). Animals were
tracheostomised and breathed spontaneously. Both femoral
arteries were cannulated with polyethylene tubing for
continuous blood pressure and heart rate recordings and for
collection of reference blood samples. Both femoral veins
were cannulated for infusion of drugs. A tube was also
placed in the left heart ventricle through the right common
carotid artery. At the end of operative procedure, heparin
(500 U/kg; Lo ¨vens, Denmark) was given to prevent clot-
ting. During the surgical preparation, a slow infusion of
saline (5 ml/kg/h) was given to avoid dehydration.
Q was determined with 15 lm radioactive microspheres
(Perkin Elmer Life Sciences, USA) [16]; the technique has
previously been described in detail [17, 18]. Spheres
labeled with three radionuclides, 141Ce, 103Ru and 95Nb,
were used in all series, allowing three Q determinations.
Approximately 150,000 spheres diluted to 0.3 ml saline
were administered at each injection over 15 s, and sam-
pling of reference blood in one femoral artery using a
peristaltic pump continued for 1 min at a rate of 0.6 ml/
min. The amount of radioactivity given was calculated by
taking small aliquots of the initial sphere volume.
At the end of the experiments, the animals were given an
overdose of anaesthesia and KCl. The choroid, anterior
uvea, retina, heart, left and right kidneys, left masseter
muscle and left brain hemisphere were dissected for mea-
surements of counts per minute (CPM) in a gamma spec-
trometer (Modiﬁed model; Nuclear Chicago, USA). In
order to obtain correct activity, background activity and
cross-over between energy channels were considered for
each sphere measurement; and in all experiments the same
three nuclides were administered to give similar cross-over
inﬂuences in all series. Regional blood ﬂow (Q) was cal-
culated by multiplying tissue CPM with the reference ﬂow
and dividing by the CPM of the reference blood sample and
expressing it as mg/min for ophthalmic tissues and as
g/min/g(tw) for other tissues. Vascular resistance (VR) was
calculated by dividing the average mean arterial pressure
(MAP) during sphere injection with Q and expressing it in
arbitrary units [u = mmHg/g/min/g(tw)]. Cardiac index
(CI) in g/min/kg(bw) and total peripheral resistance (TPRI)
in arbitrary units [U = mmHg/g/min/kg(bw)] were calcu-
lated by knowing the total amount of administered radio-
activity and the reference femoral ﬂow and CPM and MAP
[17].
In the ﬁrst series of experiments (normal rats, n = 7;
STZ rats, n = 5), the ﬁrst Q determination was performed
after a 15-min stabilization period. Five minutes later, an iv
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maintained throughout the experiment using a infusion
pump (P-2000; IVAC Medical Systems, UK) at a rate of
0.1 ml/min. After 15 min of ET-1 infusion, the second
Q determination was performed. After an additional 5 min,
BQ 123, 1 mg/kg(bw), was administered as a bolus injec-
tion. Five minutes later, the third Q determination was
performed.
In the second series of experiments (normal rats, n = 8;
STZ, n = 6), animals were pretreated with the NO-synthase
inhibitor L-NAME using a sequence of bolus injection
[10 mg/kg(bw)] followed by an iv infusion [10 mg/h/
kg(bw)] as previously described [18]. After 10 min of
L-NAME infusion, the ﬁrst microsphere injection was per-
formed. Five minutes later, iv infusion of ET-1 [60 pmol/
min/kg(bw)] was started and maintained throughout the
experiment. Additional microspheres were given 15 and
25 min later. However, the third was only given for cross-
over adjustments to resemble the other series.
In a third series of experiments (normal rats, n = 5;
STZ, n = 5), animals were pretreated with the cyclooxy-
genase inhibitor indomethacin as a bolus 5 mg/kg(bw)
followed by infusion 0.1 mg/h/kg(bw). In this series, the
ﬁrst sphere was given after a resting period and the second
after 11 min indomethacin treatment. Five minutes later
ET-1 [60 pmol/min/kg(bw)] was started and maintained for
15 min following a third sphere injection.
Drugs and statistical analysis
Endothelin-1 (human; Bachem UK, UK) was dissolved in
saline containing 0.05% rat serum albumin (Sigma-
Aldrich, Sweden). L-NAME (Nx-nitro-L-arginine methyl
ester; Sigma-Aldrich), BQ-123 sodium salt (cyclo-D-Trp-
D-Asp-Pro-D-Val-Leu; Neosystem, France) and indometh-
acin (Confortid) were diluted in saline. Statistical analysis
was performed with non-parametric tests. Within each
animal group, Wilcoxon signed rank test and Mann–
Whitney U test was applied between the normal and STZ
groups within each series. However, statistics was not
applied between the three different groups of series since
groups were considered too small for such cross-over
analysis. Non-parametric tests were chosen because of
limited group sizes. All values are given as mean ± SEM.
P\0.05 was regarded as statistically signiﬁcant.
Results
Resting conditions
Both kidneys were investigated in all series of experiments
and similar blood ﬂow measurements in the kidneys were
regarded as an indication of reliability of the microsphere
procedure (Table 1). Renal Q under resting conditions was
signiﬁcantly higher in the normal rats compared to the
STZ-diabetic animals. VR in the right and left kidneys
were 23 ± 2 and 23 ± 1 u in normal rats and signiﬁcantly
higher in STZ-diabetic animals (31 ± 1 and 32 ± 2u ,
respectively), indicating renal vasoconstriction in diabetic
animals. In the heart and skeletal muscle (masseter mus-
cle), Q and VR were comparable in normal and diabetic
rats. In the ophthalmic circulation, Q tended to be slightly
higher in normal rats as compared to STZ-rats (Table 1)
but there was no difference in VR. Retina had a very low
Q and was therefore not further evaluated. Cerebral Q was
only studied in the ﬁrst series of experiments and showed
similar levels in the two groups of animals.
Following treatment with the NO-synthase inhibitor
L-NAME, resting Q was reduced in all tissues investigated,
indicating the presence of a generalized vasodilator NO-
tone. Following L-NAME, resting renal Q was comparable
in normal and diabetic rats (Table 1). In the kidneys of
both normal and diabetic rats, VR following L-NAME was
increased compared to ﬁndings in rats without pretreatment
(71 ± 9 and 71 ± 9 u in right and left kidneys compared
to 23 ± 2 and 23 ± 1 u, respectively, in normal rats and
49 ± 3 and 52 ± 2 u compared to 31 ± 1 and 32 ± 2ui n
diabetic rats). Resting Q was not affected by cyclooxy-
genase inhibition with indomethacin.
Endothelin-1 without pretreatment
In the normal rats of the ﬁrst series of experiments, MAP
was 129 ± 6 mmHg during ﬁrst sphere injection and
increased signiﬁcantly during ET-1-infusion to 146 ±
5 mmHg at the second sphere injection (P\0.05). In the
diabetic rats, MAP was 120 ± 6 and 115 ± 8 mmHg,
respectively. Total peripheral resistance was similar in both
groups at baseline 0.36 ± 0.03 U in normal rats and
0.35 ± 0.02 U in diabetic rats (Fig. 1a). ET-1 markedly
increased the TPRI to 0.77 ± 0.14 U in normal rats
(P\0.05) whereas no signiﬁcant increase was observed in
diabetic rats 0.41 ± 0.05 U (Fig. 1a). This response was
signiﬁcantly different between the groups. CI was reduced
from 360 ± 20 to 220 ± 30 g/min/kg(bw) in normal rats
and from 350 ± 20 to 290 ± 20 g/min/kg(bw) in diabetic
rats. However, the difference between groups was not
statistically signiﬁcant (Fig. 1b).
Both kidneys showed a similar response with a signiﬁ-
cant marked reduction of Q in both animal groups during
ET-1 infusion (shown for the right kidney in Fig. 2)b y
-64 ± 11 and -47 ± 7%, respectively, compared to base-
line (P\0.05). VR increased signiﬁcantly from 23 ± 2t o
220 ± 110 u in the normal rats (P\0.05) and from
31 ± 1t o6 0± 12 u in STZ-rats (P\0.05), indicating
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pronounced in the diabetic rats.
In the heart, ET-1 induced a signiﬁcant decrease in Q in
normal rats compared to baseline (-38 ± 13%, P\0.05),
whereas no change was observed in diabetic rats
(?1 ± 14%). VR increased in the normal rats signiﬁcantly
from 27 ± 3t o3 9± 5u( P\0.05) but not in the STZ-rats
(30 ± 3t o3 2± 5 u), indicating coronary vasoconstriction
only in the normal rats. A similar response was found in the
skeletal muscle with signiﬁcantly reduced Q only in normal
rats (-52 ± 12%) and no change in diabetic rats
(?2 ± 26%; Fig. 2). In the normal rats, VR was signiﬁ-
cantly increased from 1.0 ± 0.3 to 3.4 ± 0.9 u, but not
signiﬁcantly in diabetic rats (1.3 ± 0.2 to 1.7 ± 0.7 u).
Thus, similar ﬁndings of vasoconstriction only in normal
rats were found in the skeletal muscle and the heart.
Choroidal Q signiﬁcantly increased compared to base-
line by 126 ± 71% (P\0.05) in the normal rats and by
72 ± 36% (ns) in the diabetic rats, respectively (Fig. 2).
VR was signiﬁcantly reduced in normal rats from
3.3 ± 0.9 to 1.8 ± 0.4 u (P\0.05), but the reduction
from 2.9 ± 0.5 to 2.0 ± 0.5 u was not statistically signif-
icant in diabetic rats. The difference in response between
normal and diabetic rats was not statistically signiﬁcant for
either Q or VR.
In the anterior uvea of normal rats, ET-1 signiﬁcantly
decreased Q by -32 ± 5% compared to baseline
(P\0.05), whereas it was not signiﬁcantly reduced
(-18 ± 10%)inthe STZ-rats (Fig. 2).VRwas consequently
increased from 2.8 ± 0.3 to 4.7 ± 0.3 u (P\0.05) in
normal rats, but not signiﬁcantly in STZ-rats (3.2 ± 0.2 to
4.1 ± 0.7 u).
The ﬁndings from choroid differed markedly from
ﬁndings in other investigated tissues including other vas-
cular beds within the eye, such as the anterior uvea. Similar
to the choroid, an increase in Q induced by ET-1 was
observed in the brain of normal rats (?38 ± 20%, ns) and
of diabetic rats (?32 ± 17%, P\0.05).
ET-1 effects during administration of BQ-123
Administration of BQ-123 during the ET-1-infusion did not
induce any additional effect on MAP in the healthy animals
(146 ± 5 mmHg before and 150 ± 5 mmHg after BQ-
123) or in the diabetic rats (115 ± 8 mmHg before and
118 ± 10 mmHg after BQ-123), although MAP at this
time was signiﬁcantly different between animal groups.
TPRI remained at a high level in healthy rats
(0.82 ± 0.07 U) and increased signiﬁcantly in the diabetic
rats (0.52 ± 0.04 U, P\0.05; Fig. 1a). CI remained
Table 1 Local blood ﬂow in the examined tissues under resting condition before endothelin-1 administration in normal and STZ-diabetic rats
Tissue (unit) Type of rat Blood ﬂow
No pretreatment
normal (n = 7),
STZ (n = 5)
Blood ﬂow
L-NAME pretreated
normal (n = 8),
STZ (n = 6)
Blood ﬂow
indomethacin pretreated
normal (n = 5),
STZ (n = 5)
Right kidney [g/min/g(tw)] Normal 5.8 ± 0.3* 2.3 ± 0.3 6.1 ± 0.3
STZ 4.0 ± 0.4 2.7 ± 0.1 3.3 ± 0.4
Left kidney [g/min/g(tw)] Normal 5.7 ± 0.3* 2.3 ± 0.2 5.7 ± 0.3
STZ 3.9 ± 0.4 2.5 ± 0.1 3.1 ± 0.5
Heart [g/min/g(tw)] Normal 4.2 ± 0.4 2.8 ± 0.2* 4.8 ± 0.5
STZ 3.6 ± 0.4 2.2 ± 0.1 3.6 ± 0.4
Skeletal muscle [g/min/g(tw)] Normal 0.16 ± 0.03 0.06 ± 0.01* 0.13 ± 0.04
STZ 0.15 ± 0.03 0.12 ± 0.02 0.13 ± 0.05
Choroid (mg/min) Normal 59 ± 14 6 ± 24 7 ± 15
STZ 45 ± 61 0 ± 35 2 ± 12
Anterior uvea (mg/min) Normal 49 ± 61 6 ± 24 8 ± 7
STZ 38 ± 21 8 ± 24 1 ± 6
Retina (mg/min) Normal 2 ± 12 ± 13 ± 1
STZ 4 ± 12 ± 11 ± 1
Brain (left hemisphere) [g/min/g(tw)] Normal 0.84 ± 0.07
STZ 0.80 ± 0.07
Data are the mean ± SEM. Mann–Whitney U test between groups
STZ Streptozotocin, L-NAME a NO synthase inhibitor, Indomethacin a cyclooxygenase inhibitor
* P\0.05
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123reduced at 190 ± 10 and 220 ± 20 g/min/kg(bw) in nor-
mal and diabetic rats, respectively (Fig. 1b).
In the right kidney, administration of BQ-123 aug-
mented the ET-1-induced Q reduction in normal rats,
whereas in the STZ-rats, Q reduction was not signiﬁcantly
further affected by BQ-123. The level of Q reduction was
signiﬁcantly different between normal and diabetic animals
with a more pronounced effect in the normal animals.
In the heart of normal rats, ET-1-induced Q reduction
was attenuated by administration of BQ-123, from
-38 ± 13 to -19 ± 17% compared to baseline, but there
was no signiﬁcant change in VR. In diabetic rats, the
coronary Q was not affected by either ET-1 alone or ET-1/
BQ-123.
In the skeletal muscle of normal rats, Q remained
reduced after BQ-123 administration. In STZ-rats, no
signiﬁcant change was observed in skeletal muscle
Q (Fig. 2).
In the choroid of normal rats, BQ-123 did not signiﬁ-
cantly affect the ET-1-induced increase in Q. However, in
the STZ-rats, administration of BQ-123 abolished the ET-
1-induced increase in Q (Fig. 2). VR was signiﬁcantly
increased from 2.0 ± 0.5 to 3.3 ± 0.7 u (P\0.05) in the
diabetic rats, indicating vasoconstriction. The difference
between normal and STZ-rats was signiﬁcant regarding
both Q and VR.
In the anterior uvea of normal rats, administration of
BQ-123 during ET-1-infusion did not statistically affect Q,
whereas in the diabetic rats, Q was signiﬁcantly reduced to
-33 ± 8% of baseline Q (P\0.05; Fig. 2). However,
there was no signiﬁcant difference between the groups.
In the brain of normal rats, Q signiﬁcantly increased
during combined BQ-123/ET-1 administration compared to
ET-1 alone to ?76 ± 32% of baseline blood ﬂow
(Fig. 2a). In contrast, in the STZ-rats, BQ-123 abolished
the ET-1-induced increase in cerebral Q (Fig. 2b). The
difference in response to BQ-123 during ET-1 infusion in
the brain was signiﬁcant between the animal groups.
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and cyclooxygenase
MAP in normal rats during NO-synthase inhibition with
L-NAME was 149 ± 6 mmHg and did not increase further
when ET-1 was administered (142 ± 10 mmHg). In dia-
betic rats, MAP was 129 ± 2 and 122 ± 3 mmHg,
respectively. In the series of experiments with indometha-
cin, MAP was 121 ± 7 mmHg before and 129 ± 5 mmHg
during ET-1-infusion in normal rats, and 121 ± 7 and
124 ± 6 mmHg, respectively, in the diabetic rats.
In the right kidney, where marked vasoconstriction was
induced by ET-1 alone in both normal and STZ-rats, the
ET-1-induced reduction in Q was maintained following
both L-NAME and indomethacin pretreatment in normal
and STZ-rats (Fig. 3).
In the heart, where ET-1-induced vasoconstriction
was only observed in normal rats, the reduction of Q by
ET-1 was less pronounced after L-NAME. Following
indomethacin pretreatment, no effect on Q was
observed (Fig. 3). In the heart of STZ-rats, a slight but
signiﬁcant reduction in Q was only observed following
L-NAME.
In skeletal muscle of normal rats, ET-1 alone induced
vasoconstriction, which was less pronounced following
pretreatment with L-NAME and abolished by pretreatment
with indomethacin. In the skeletal muscle of STZ-rats,
Q was signiﬁcantly slightly reduced only after L-NAME
(Fig. 3).
In the choroid of both normal and STZ-rats, the increase
in Q induced by ET-1 was abolished by L-NAME pre-
treatment (Fig. 3), and instead a signiﬁcant reduction in
Q occurred in both groups. In contrast, following cyclo-
oxygenase inhibition with indomethacin, choroidal Q was
increased by ET-1 in both healthy and diabetic rats.
In the anterior uvea of normal rats, signiﬁcant reductions
of Q were induced by ET-1 irrespective of pretreatment. In
diabetic rats, a similar response was observed; however,
the reduction in Q was statistically signiﬁcant only fol-
lowing L-NAME pretreatment (Fig. 3).
Discussion
In the present study, the microsphere method was applied
to investigate hemodynamics in normal rats and in rats with
STZ-induced diabetes mellitus. Evidence for renal vaso-
constriction was found in diabetic animals under baseline
conditions compared to non diabetic rats. ET-1 induced
intense vasoconstriction in all tissues in the normal rats
except in the choroid of the eye and in the brain. A similar
response was observed in the STZ-diabetic rats, although
the effect of ET-1 was less pronounced. Pretreatment with
L-NAME abolished the ET-1-induced vasodilation in the
choroid of both healthy and diabetic animals indicating
involvement of NO, whereas administration of BQ-123
reduced the ET-1-induced vasodilation only in diabetic
animals, suggesting differential involvement of receptors in
the response to ET-1 in normal and STZ-rats.
Streptozotocin is an antibiotic, structurally a glucosa-
mine derivative of nitrosurea. It causes hyperglycemia
mainly by its direct cytotoxic action on the pancreatic beta
cells [13, 19]. It is a widely used rat animal model for
diabetes demonstrating many similarities with human dia-
betes regarding endothelial cell function. In the rat model
of STZ-induced diabetes, elevated plasma ET-1 levels [13],
increase in immunoﬂuorescence to anti-ET-1 within the
capillary bed and veins of the retina [14] and reduced
progression of diabetic nephropathy by ET A-receptor
inhibition [15] have been demonstrated. This model has
previously been successfully used in conjunction with the
microsphere technique for measurement of central and
regional hemodynamics [16, 18, 20]. In the present study,
although the duration of hyperglycemia was short, signiﬁ-
cant alterations in resting Q and response to ET-1 were
identiﬁed in diabetic animals compared to the healthy rats.
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123However, the hyperglycemia per se might partly be
responsible for differences in hemodynamic response, and
the length of established diabetes should also be considered
of possible importance.
Under resting conditions, evidence for renal vasocon-
striction was found in the diabetic animals. In other
investigated tissues, VR was comparable between normal
and diabetic rats. Following treatment with the NO-syn-
thase inhibitor L-NAME, resting Q was reduced in all
investigated tissues, indicating the inﬂuence of vasodilating
NO. This ﬁnding is well in line with previous studies in the
STZ-rat [20]. Generalized vasoconstriction following
inhibition of NO synthesis, although to a different extent in
various tissues, has also been observed in other rat models
of diabetes, such as the Zucker diabetic fatty rat [21]a s
well as in the ocular circulation of diabetic humans [22].
The ET-1-induced intense vasoconstriction in most non-
ocular tissues could explain a compensatory reduction in
CI, which was more pronounced in the normal than in the
diabetic animals. The vasoconstrictive effect of ET-1 in the
kidneys was less pronounced in this model of diabetes.
Reduced ET-1-induced vasoconstriction in diabetes has
previously been demonstrated in the rat isolated mesenteric
arteries [13, 23] and coronary circulation of both experi-
mental animals [24] and humans [25].
In the heart and the skeletal muscle, ET-1 induced
vasoconstriction in normal animals, whereas in the diabetic
animals, a small ET-1-induced reduction in regional blood
ﬂow was observed only following pretreatment with
L-NAME. This ﬁnding suggests that, in the diabetic ani-
mals, continuous formation of NO by the vascular endo-
thelial cells reduces the vasoconstrictive effect of ET-1.
Also, in the mesenteric arteries of the diabetic Goto-Ka-
kizaki rat, vasoconstriction induced by ET-1 was reduced
compared to non-diabetic Wistar rats, and the effect of ET-
1 was enhanced by inhibition of NO synthesis [23]. In the
hearts of early STZ-diabetic rats, increased expression of
NO-synthase was inhibited by treatment with an ET-A-
receptor antagonist in support of an important interrela-
tionship between ET-1 and NO [26].
In contrast to the ET-1-induced intense vasoconstriction
in most tissues of both normal and diabetic rats, ET-1 was
found to induce an increase in blood ﬂow in the choroid of
the eye and to some extent in the brain. Pretreatment with
L-NAME abolished the ET-1-induced vasodilation in the
choroid of both healthy and diabetic animals, indicating the
involvement of NO in both animal groups.
The choroidal vascular bed is characterized by relatively
wide but ﬂat capillaries with fenestrated capillary walls and
a high blood ﬂow. The high ﬂow rate results in a high
oxygen tension in the tissue [27, 28]. The capillary wall is
permeable to plasma proteins such as vitamin A. Choroidal
blood ﬂow contributes signiﬁcantly to the nourishment of
the retina [27, 28] and may also contribute to temperature
regulation. Retinal blood vessels, on the other hand, are the
continuous type with tight junctions constituting the blood–
retinal barrier. Retinal blood ﬂow is low and is autoregu-
lated in contrast to the choroidal blood ﬂow [27, 28].
In a study of spontaneous oscillations in choroidal
arterioles in rabbits, ET-1 was found to increase vasomo-
tion [29]. In this model of in situ-perfused isolated rabbit
eyes, ET-1 induced an initial short and weak vasodilating
effect followed by a strong and long-lasting vasoconstrictor
tone. Similar ﬁndings of transient choroidal vasodilation
followed by vasoconstriction was observed using the laser
Doppler technique in rabbits [30]. During the present
experimental conditions, a vasodilating effect of ET-1 was
observed in the choroid. The results are consistent with
ﬁndings in a study in rabbits using the hydrogen clearance
method where intravitreal administration of ET-1 induced a
long-lasting increase in choroidal blood ﬂow whereas ret-
inal blood ﬂow was reduced [31]. A difference in reactivity
between vascular beds of the choroid and anterior uvea has
previously been demonstrated in the STZ-diabetic model
[18, 20].
ET-1 exerts its effect through ET A- and B-receptors.
ET A-receptors are distributed on the vascular endothelial
cells and activation generally induces vasoconstriction. ET
B-receptors, on the other hand, are located on vascular
endothelial cells causing vasodilation through release of
NO and prostacyclin, but may also be present on vascular
smooth muscle cells causing vasoconstriction [12]. The net
effect of ET-1 depends mainly on overall ET receptor
proﬁle. In the rat retina, ET B-receptors have been shown
to be the dominating receptor subtype [32]. The ﬁndings in
the present study of ET-1-induced vasodilation in the
choroid suggest a predominance of vasodilatory ET
B-receptors in the choroid. It might also be that, with the
dose of ET-1 used in the present study, the vasodilatory ET
B-receptor response is dominant. ET B-receptors have been
found in the outer choroid [33]. Efﬁcient vasodilatory
mechanisms in the choroid could be of importance to
maintain retinal integrity and reduce the susceptibility of
the retina to vasoconstrictive agents.
In diabetic patients, increased levels of ET-1 in plasma
and vitreous humor have been found [8, 34]. In strepto-
zotocin-diabetic rats, an increase in resistivitiy index for
retinal blood ﬂow indicating vasoconstriction was pre-
vented by treatment with the ETA/B-receptor antagonist
bosentan, suggesting endothelin involvement in this func-
tional change [35]. Furthermore, in the same study, ET-1
and ET-3 immunoreactivity and endothelin receptor con-
centrations were increased in the retina [35]. In diabetic
BB/W rats following 6 months of diabetes, signiﬁcant
increases in ET-1, ET-3, ET(A) and ET(B) mRNA
expressions compared to age-matched control rats were
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1 expression was found to be regulated by ERK5 in the
endothelial cells and retina of diabetic rats [37]. Consistent
ﬁndings of upregulation of ET-1 and increased expression
of ET A- and ET B-receptors in the retinal vasculature have
been found in diabetes [37]. Although there are no such
observations in choroidal blood vessels, it seems likely that
diabetes may also induce changes in expression of ET-1
and receptor proﬁle of ET A- and ET B-receptors in this
vascular bed.
In the present study, administration of the selective ET
A-receptor antagonist BQ-123 reduced the ET-1-induced
choroidal vasodilation only in diabetic animals, suggesting
differential involvement of ET receptors in the response to
ET-1 in normal and STZ-rats. A similar ﬁnding, but less
pronounced, was observed in the brain of diabetic rats. It
may be hypothesized that BQ-123 was less selective in the
diabetic animals during the present experimental condi-
tions with high glucose. In addition to ET A-receptor
inhibition, BQ-123 has been shown to inhibit vascular
smooth muscle cell release of vasoactive peptides and
reduce oxidative stress under hyperglycemia [38].
Pretreatment with the cyclooxygenase inhibitor indo-
methacin did not signiﬁcantly affect blood ﬂow or response
to ET-1 in either normal or diabetic animals. Although
prostacyclins are produced by the vascular endothelium
[39], the results of the present study suggest that, in this
animal model, their inﬂuences are of less importance.
In summary, in the present study of early STZ-diabetic
animals, evidence for altered vascular endothelial response
to ET-1 with and without pretreatment with the NO-syn-
thase inhibitor L-NAME was found. ET A-receptor inhi-
bition using BQ-123 revealed differences in this diabetic
model and non-diabetic rats, particularly in ocular circu-
lation. Further studies are of importance to conﬁrm the
relationship to diabetic microvascular complications.
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